

<b>ZALCITABINE (DDC)* (Updated January 2007) DISCONTINUED IN 2006</b>		
<b>Trade Name</b>	Hivid	
<b>Classification</b>	Nucleoside Reverse Transcriptase Inhibitor	
<b>Form</b>	0.375-, 0.75-mg tablets	
<b>Dosing Recommendations</b>	0.75 mg tid	
<b>Renal Impairment Dosing</b>	<b>CrCl (mL/min)</b>	<b>Dose</b>
	10-40	0.75 mg bid
	<10	0.75 mg qd
<b>Food Effect</b>	Can be taken on an empty stomach or with food (ddC AUC ↓ 14%)	
<b>Oral Bioavailability</b>	85%	
<b>Serum Half-life</b>	1.2 hour	
<b>Intracellular Half-life</b>	3 hours	
<b>Elimination</b>	Renal excretion 70%	
<b>Adverse Events</b>	Peripheral neuropathy, pancreatitis, stomatitis, lipoatrophy Lactic acidosis with hepatic steatosis is a rare but potentially life-threatening toxicity	
<b>FDA Pregnancy Category</b>	C	
<b>Long-Term Animal Carcinogenicity Studies</b>	Positive (rodent, thymic lymphomas)	
<b>Animal Teratogen Studies</b>	Positive (rodent-hydrocephalus at high dose)	
<b>Black Box Warnings</b>	<p>Zalcitabine can cause severe peripheral neuropathy; use with caution in patients with preexisting neuropathy.</p> <p>In rare cases, zalcitabine can cause pancreatitis; therapy should be withheld until pancreatitis is excluded.</p> <p>Rare cases of hepatic failure and death have been reported among patients with underlying hepatitis B infection.</p> <p>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination.</p>	
<b>Drugs to Avoid</b>	<b>As part of the ARV regimen:</b> Didanosine Lamivudine Stavudine Zidovudine	

<b>Cautious Use or Dose Adjustment</b>	
<b>Antacids</b>	<b>Aluminum- or magnesium-containing antacids:</b> ↓ ddC absorption ~25% – Do not take simultaneously (take 1 hour before or 2 hours after meals)
<b>Antifungals</b>	<b>Intravenous pentamidine:</b> Possible development of fulminant pancreatitis – Zalcitabine therapy should be interrupted during IV pentamidine
<b>Histamine H2 Blockers</b>	<b>Cimetidine:</b> ↓ elimination of ddC– Monitor for signs of toxicity
<b>Uricosuric Agents</b>	<b>Probenecid:</b> ↓ elimination of ddC– Monitor for signs of toxicity
* Zalcitabine was discontinued in the last quarter of 2006.	